{
    "id": 16629,
    "fullName": "CRKL amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CRKL amplification indicates an increased number of copies of the CRKL gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1399,
        "geneSymbol": "CRKL",
        "terms": [
            "CRKL"
        ]
    },
    "variant": "amp",
    "createDate": "01/15/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3987,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric adenocarcinoma cells harboring CRKL amplification were sensitive to Sprycel (dasatinib), resulting in decreased phosphorylation of Crkl and reduced cell growth in culture (PMID: 22591714).",
            "molecularProfile": {
                "id": 16907,
                "profileName": "CRKL amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4344,
                    "pubMedId": 22591714,
                    "title": "The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22591714"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4489,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplification of NRAS, MAPK1, and CRKL were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18237,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4488,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion, and amplification of NRAS, MAPK1, and CRKL in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18237,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4496,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion and amplification of CRKL and MAPK1 were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18262,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13945,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in disease progression after 1 cycle of treatment in a patient with Erbb2 (HER2) and CRKL amplified gastric adenocarcinoma (PMID: 29409051; NCT02015169).",
            "molecularProfile": {
                "id": 29890,
                "profileName": "CRKL amp ERBB2 amp"
            },
            "therapy": {
                "id": 1498,
                "therapyName": "Capecitabine + Lapatinib + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11372,
                    "pubMedId": 29409051,
                    "title": "Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409051"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12015,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquisition of CRKL amplification was identified in an EGFR-mutant non-small cell lung carcinoma patient who developed progressive disease after treatment with Tarceva (erlotinib) (PMID: 22586683).",
            "molecularProfile": {
                "id": 31786,
                "profileName": "CRKL amp EGFR mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16907,
            "profileName": "CRKL amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7403,
                    "name": "Dasatinib",
                    "profileName": "CRKL amp"
                }
            ]
        },
        {
            "id": 18237,
            "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18262,
            "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29890,
            "profileName": "CRKL amp ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31786,
            "profileName": "CRKL amp EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}